Log in to search using one of your social media accounts:

 

ASH: Oral Edoxaban Noninferior to Dalteparin for CA - Linked VTE
Oral edoxaban found noninferior for recurrent venous thromboembolism or major bleeding (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 13, 2017 Category: Respiratory Medicine Tags: Internal Medicine, Oncology, Pharmacy, Pulmonology, Conference News, Source Type: news

How Physicians Perform Prehospital ECMO on the Streets of Paris
The objective of ECPR is to perfuse the brain while the cause of the cardiac arrest is sought and treated at a specialty hospital (e.g., by coronary angiography, CT scan, etc.). Indeed, the primary objective is to obtain return of spontaneous circulation (ROSC), however, long-term survival depends on the neurological prognosis of the patient. Once ECPR has been initiated, acceptable blood flow is restored to the whole body, and especially to the brain and coronary arteries in order to limit ischemic consequences. Many studies, both clinical and experimental, have shown that the blood flow delivered by ECPR is much highe...
Source: JEMS Patient Care - December 1, 2017 Category: Emergency Medicine Authors: Alice Hutin, MD, MSc Tags: Patient Care Cardiac & Resuscitation Source Type: news

A Medical Director's Personal Experience with ECMO Reveals Several Lessons Learned
My personal experience with ED ECMO What does it take to save the life of someone who's in shock and suffering from an acute massive pulmonary embolism? The answer is a comprehensive system of medical care that starts in the field with well-trained providers and is seamlessly backed up by hospitals that can provide highly sophisticated treatments that can now be started in the ED. As a cardiologist and the operational medical director for the city of Richmond, Va., and the surrounding Henrico County, I've had the privilege of helping to develop a comprehensive, regional system of care. In this article, I'm going t...
Source: JEMS Patient Care - December 1, 2017 Category: Emergency Medicine Authors: Joseph P. Ornato, MD, FACP, FACC, FACEP Tags: Patient Care Cardiac & Resuscitation Source Type: news

Boehringer Ingelheim launches RE-COVERY DVT/PE ™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim launches RE-COVERY DVT/PE ™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA approves Pradaxa ® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
FDA approves Pradaxa ® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Positive CHMP opinion for Pradaxa ® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots
Positive CHMP opinion for Pradaxa ® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New findings from two studies support substantial benefit of Pradaxa ® for prevention of recurrent deep vein thrombosis and pulmonary embolism
New findings from two studies support substantial benefit of Pradaxa ® for prevention of recurrent deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data analyses show consistent efficacy and safety profile of Pradaxa ® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
New data analyses show consistent efficacy and safety profile of Pradaxa ® in broad range of patients with acute deep vein thrombosis or pulmonary embolism* (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Application submitted to the European Medicines Agency (EMA) for use of Pradaxa ® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
Application submitted to the European Medicines Agency (EMA) for use of Pradaxa ® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism
New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
Pradaxa ® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

French Oncologists Upgrade Mesothelioma Standard of Care
Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma. Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival. “This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told Asbestos.com. “Clearly, this drug can change the natural history of this tumor.” Bevaci...
Source: Asbestos and Mesothelioma News - November 20, 2017 Category: Environmental Health Authors: Daniel King Tags: American Society of Clinical Oncology Avastin bevacizumab Bichat-Claude Bernard Hospital French Cooperative Thoracic Intergroup Gerard Zalcman National Comprehensive Cancer Network nintedanib Ofev pleural mesothelioma chemotherapy Source Type: news

General practitioners accurately diagnose DVT with US
General practitioners can be trained in compression ultrasonography to accurately...Read more on AuntMinnie.comRelated Reading: Role of imaging modalities is changing for PE diagnosis Ultrasound elevates diagnosis of pulmonary embolism Can ultrasound for deep vein thrombosis cause a PE? Ultrasound screening catches embolism in cancer patients AAOS includes DVT US on Choosing Wisely list (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 17, 2017 Category: Radiology Source Type: news

New Practice Discharges More Pulmonary Embolism Patients New Practice Discharges More Pulmonary Embolism Patients
A carefully defined group of pulmonary embolism patients can avoid hospitalization, saving healthcare systems time and money, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2017 Category: Consumer Health News Tags: Emergency Medicine News Source Type: news

Apixaban -- metabolism, pharmacologic properties and drug interactions
(Bentham Science Publishers) New oral anticoagulants (NOACs) represent direct-acting drugs functioning selectively for one specific clotting factor. Their clinical indications are the prophylaxis and treatment of deep venous thrombosis and pulmonary embolism, the prevention of atherothrombotic episodes of individuals with acute coronary syndromes and atrial fibrillation (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2017 Category: International Medicine & Public Health Source Type: news

Editor's highlight: pulmonary vascular thrombosis in rats exposed to inhaled sulfur mustard - McGraw MD, Osborne CM, Mastej EJ, Di Paola JA, Anderson DR, Holmes WW, Paradiso DC, Garlick RB, Hendry-Hofer TB, Rancourt RC, Smith RW, Burns C, Roe GB, Rioux JS, White CW, Veress LA.
Sulfur mustard (SM) is a chemical warfare agent. When inhaled, SM causes significant injury to the respiratory tract. Although the mechanism involved in acute airway injury after SM inhalation has been well described previously, the mechanism of SM's contr... (Source: SafetyLit)
Source: SafetyLit - October 4, 2017 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

Your NEJM Group Today: Thrombophilia Testing Review Article / Self-Grooming Disorders / California Pulmonary & Sleep Opportunities (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Clinical Practice Center: Review Article: Most patients with venous thromboembolism do not … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 26, 2017 Category: Primary Care Source Type: news

DVT (Deep Vein Thrombosis) and Pulmonary Embolism (PE) Quiz
Title: DVT (Deep Vein Thrombosis) and Pulmonary Embolism (PE) QuizCategory: MedicineNet QuizCreated: 7/31/2014 12:00:00 AMLast Editorial Review: 9/20/2017 1:12:43 PM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 20, 2017 Category: Cardiology Source Type: news

Studies support anti-stroke PFO closure devices from Abbott, Gore
Sykes and Clark; licensee BioMed Central Ltd. A trio of studies published this week in the New England Journal of Medicine showed that devices from Abbott (NYSE:ABT) and W.L. Gore & Assoc. designed to close a heart defect lowered the risk of a recurring episode in certain cryptogenic stroke patients. Long-term results from the 980-patient Respect trial of the Amplatzer device Abbott acquired along with St. Jude Medical this year, along with data from the Reduce study of Gore’s Helex and Cardioform and the French Close study of PFO closure devices with CE Mark approval, showed that they reduced the risk of re...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Surgical Abbott Structural heart W.L. Gore & Associates Source Type: news

Diving accident-induced arterial gas embolism - Nijk PD, van Rees Vellinga TP, van Lieshout JM, Gaakeer MI.
BACKGROUND: During scuba diving, nitrogen dissolves into the body tissues due to elevated pressure under water. During a sudden drop in pressure due to a rapid return to the water surface, arterial gas embolism can arise from pulmonary barotrauma. In a lat... (Source: SafetyLit)
Source: SafetyLit - September 9, 2017 Category: International Medicine & Public Health Tags: Drowning, Suffocation Source Type: news

For post-menopausal women, vaginal estrogens do not raise risk of cancer, other diseases
This study, the first to examine potential adverse health effects in users of vaginal estrogen compared with non-users, suggests that vaginal estrogen therapy is a safe treatment for genitourinary symptoms such as burning, discomfort, and pain during intercourse associated with menopause.AUTHORSThe paper ’s authors are Dr. Carolyn Crandall of UCLA; Kathleen Hovey of the State University of New York at Buffalo; Christopher Andrews of the University of Michigan; Dr. Rowan Chlebowski of City of Hope; Marcia Stefanick of Stanford University; Dr. Dorothy Lane of the State University of New York at Ston y Brook; Dr. Jan Sh...
Source: UCLA Newsroom: Health Sciences - August 16, 2017 Category: Universities & Medical Training Source Type: news

In assessing risk of hormone therapy for menopause, dose — not form — matters
FINDINGSWhen it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered — taking a pill versus wearing a patch on one’s skin — doesn’t affect risk or benefit, researchers at UCLA and elsewhere have found. But with the commonly used conjugated equine estrogen, plus progestogen, the dosage does. Higher doses, especially over time, are associated with greater risk of problems, including heart disease and some types of cancer, especially among obese women.BACKGROUNDThe Women ’s Health Initiative established the potential of estrogen therapy to increase or decrea...
Source: UCLA Newsroom: Health Sciences - July 27, 2017 Category: Universities & Medical Training Source Type: news

Risk factors for deep vein thrombosis and pulmonary embolism after traumatic injury: a competing risks analysis - Van Gent JM, Calvo RY, Zander AL, Olson EJ, Sise CB, Sise MJ, Shackford SR.
BACKGROUND: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is typically reported as a composite measure of the quality of trauma center care. Given recent data suggesting post-injury DVT and PE are distinct ... (Source: SafetyLit)
Source: SafetyLit - July 15, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Prevalence of Pulmonary Embolism Among SLE Discharges Prevalence of Pulmonary Embolism Among SLE Discharges
This study takes a closer look.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 14, 2017 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Novel PET tracer detects small blood clots
(Society of Nuclear Medicine) Blood clots in veins and arteries can lead to heart attack, stroke, and pulmonary embolism, which are major causes of mortality. In the featured article of The Journal of Nuclear Medicine's July 2017 issue, German researchers show that targeting GPIIb/IIIa receptors, the key receptor involved in platelet clumping, with a fluorine-18 labeled ligand is a promising approach for diagnostic imaging. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2017 Category: International Medicine & Public Health Source Type: news

Managing Intra-operative Acute PE During General Anesthesia Managing Intra-operative Acute PE During General Anesthesia
Pulmonary embolism occurring during surgery is a rare and serious complication, and difficult to diagnose under anesthesia. How was it detected in this patient?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2017 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Bio2 touts pivotal data on Angel catheter-filter combo
This study of a combined IVC filter/central venous catheter was the culmination of a panel of dedicated investigators with careful guidance by the FDA,” primary investigator Dr. Victor Tapson said in prepared remarks. “The efficacy and safety of the device, simple bedside placement, and the need to remove it before discharge make it very appealing. Nearly the entire cohort had crucial, yet short-term filter needs so that discharge without a filter was preferred.” The device is the 1st to be cleared by the FDA for PE prophylaxis in critically ill patients contraindicated to anticoagulation. “The publ...
Source: Mass Device - June 30, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Catheters Clinical Trials Vascular BiO2 Medical Source Type: news

Portola shares soar after FDA approves clot preventing drug
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Portola blood-thinner to prevent clots
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. FDA approves Portola blood-thinner to prevent clots
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. FDA approves Portola blood-thinner to prevent blood clots
(Reuters) - The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 5, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. SentreHeart enters pivotal phase after hitting Lariat study milestone SentreHeart can launch the 2nd, pivotal phase in the Amaze study of its Lariat device, after hitting the mark in the 1st, 100-patient stage. Like the Watchma...
Source: Mass Device - June 5, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

SentreHeart enters pivotal phase after hitting Lariat study milestone
SentreHeart can launch the 2nd, pivotal phase in the Amaze study of its Lariat device, after hitting the mark in the 1st, 100-patient stage. Like the Watchman anti-stroke device made by Boston Scientific (NYSE:BSX), Lariat is designed to occlude the left atrial appendage, but unlike Watchman it’s intended to help treat atrial fibrillation alongside pulmonary vein isolation. The FDA approved an expansion of the study, which can now enroll another 500 patients after an independent data monitoring committee reviewed the data against preset safety and performance criteria, Redwood City, Calif.-based S...
Source: Mass Device - June 5, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Food & Drug Administration (FDA) Cardiac Rhythm Management SentreHeart Source Type: news

New guidelines for in-flight emergencies, proposed
All planes should carry defibrillators, say experts Related items fromOnMedica Fainting after air travel could be a sign of pulmonary embolism European advice launched on heart failure Safety questions over adrenaline for cardiac arrest CPR training drive for public to focus on youth (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 5, 2017 Category: UK Health Source Type: news

Medtronic recalls Kyphon bone cement
Medtronic (NYSE:MDT) is recalling some of its Kyphon bone cement after discovering a misalignment issue with the instrument that delivers the cement. The Fridley, Minn.-based company sent a letter to customers last month detailing the issue with the Kyphon directional bone filler, saying it received 2 reports that “the directional arrow at the proximal end of the instrument may not correctly align with the cut‐out opening on the distal end of the instrument.” That means the cement could be injected in “a direction unintended by the surgeon,” Medtronic said in the letter. The problem hasn&rsqu...
Source: Mass Device - June 1, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Orthopedics Recalls Spinal Medtronic Source Type: news

UPDATE: Medtronic recalls Kyphon bone cement device
This article originally and incorrectly stated that Medtronic is recalling the Kyphon bone cement, not the filler instrument that is being recalled. ↩ The post UPDATE: Medtronic recalls Kyphon bone cement device appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 1, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Orthopedics Recalls Spinal Medtronic Source Type: news

BTG's PE Device Works Faster and at Lower Doses in Study BTG's PE Device Works Faster and at Lower Doses in Study
British pharmaceutical firm BTG said its EKOS combination therapy device for pulmonary embolism (PE) was effective using smaller drug dosages and shorter treatment periods than the current standard.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 30, 2017 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 25, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Artificial pancreas: These companies are racing to make one Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that eff...
Source: Mass Device - May 25, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Ultrasound-drug combo treats pulmonary embolism in less time with fewer drugs
When venous clots break off and travel through a patient’s circulatory system, they can become trapped in the lung and block blood flow. This strains the heart’s ability to pump blood through the lungs and can ultimately lead to heart failure. Traditionally, patients with pulmonary embolisms are treated overnight with systemic infusions of tissue plasminogen activator. But, according to Dr. Victor Tapson at Cedars-Sinai Medical Center in Los Angeles, large doses of tPA are associated with side effects including intracranial bleeding and smaller doses can be safer and just as effective as the larger, c...
Source: Mass Device - May 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Vascular Wall Street Beat BTG Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 22, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. BoneSupport launches trial of antibiotic-eluting bone graft BoneSupport said today that the 1st patient has been enrolled in the pivotal investigational device exemption trial for its injectable antibiotic-eluting bone graft su...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

BTG touts Ekos data from pulmonary embolism trial
BTG (LON:BTG) touted data today from the Optalyse PE trial showing that pulmonary embolism can be treated effectively with Ekos over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. The 101-patient trial randomized participants to receive therapeutic anticoagulation and Ekos acoustic pulse thrombolysis therapy at different doses for different lengths of time. The 1st group received 4 milligrams per catheter of tissue plasminogen activator over 2 hours, while the 2nd cohort received the same dose over 4 hours. The 3rd group was treated with 6 milligrams per catheter o...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Wall Street Beat BTG Source Type: news

BTG's pulmonary embolism device work faster and at lower doses in study
LONDON (Reuters) - British pharmaceutical firm BTG said on Monday its EKOS combination therapy device for pulmonary embolism (PE) was effective using smaller drug dosages and shorter treatment periods than the current standard. (Source: Reuters: Health)
Source: Reuters: Health - May 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Perioperative Aspirin for Venous Thromboembolism Prevention Perioperative Aspirin for Venous Thromboembolism Prevention
This study investigated whether perioperative aspirin is effective in the prevention of post-surgical venous thromboembolism, including deep vein thrombosis and pulmonary embolism.Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 22, 2017 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Pulmonary embolism following severe traumatic brain injury: incidence, risk factors and impact outcome - Bahloul M, Chelly H, Regaieg K, Rekik N, Bellil S, Chaari A, Bouaziz W, Chabchoub I, Haddar S, Hamida CB, Bouaziz M.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - May 19, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

IVC Filters Still a Question Mark for Prevention in Trauma (CME/CE)
(MedPage Today) -- Trends in use don't match up with pulmonary embolism rates (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - May 10, 2017 Category: Respiratory Medicine Source Type: news

SNMMI publishes appropriate use criteria for V/Q imaging in pulmonary embolism
(Society of Nuclear Medicine) The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria for ventilation/perfusion (V/Q) imaging in pulmonary embolism. This is the second in a series of new AUC developed by SNMMI in its role as a qualified provider-led entity under the Medicare Appropriate Use Criteria program for advanced diagnostic imaging. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2017 Category: Global & Universal Source Type: news

Bypassing Clinical Decision Support Tools for Imaging in the ED Bypassing Clinical Decision Support Tools for Imaging in the ED
What happens when emergency department providers ignore CDS alerts and send suspected pulmonary embolism cases straight to the scanner?Medscape Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2017 Category: Consumer Health News Tags: Radiology Viewpoint Source Type: news

Inari Medical wins FDA nod for ClotTriever peripheral thrombectomy device
Inari Medical said today that the FDA granted pre-market approval in February for its ClotTriever thrombectomy device Feb. 16 and already has the 1st commercial procedure under its belt. Irvine, Calif.-based Inari said the ClotTriever device is designed to remove blood clots from large vessels in the peripheral vasculature. The company also makes the FlowTriever device, which is designed to retrieve pulmonary embolisms. “The ClotTriever system is the 2nd product offering in Inari’s product portfolio,” CEO Bill Hoffman said in prepared remarks.  “The ClotTriever is curre...
Source: Mass Device - April 10, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Wall Street Beat Inari Medical Peripheral Artery Disease Source Type: news

Role of imaging modalities is changing for PE diagnosis
The use of ventilation/perfusion SPECT scans to rule out pulmonary embolism...Read more on AuntMinnie.comRelated Reading: Video from ECR 2017: Dr. Martine Rémy-Jardin on pulmonary embolism Ultrasound elevates diagnosis of pulmonary embolism Triple rule-out CT offers one-stop shop for chest pain Can ultrasound for deep vein thrombosis cause a PE? Societies issue imaging guidelines for chest pain (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 31, 2017 Category: Radiology Source Type: news

No Increased Risks for DOAC Use Versus Warfarin in VTE
Direct oral anticoagulants not linked to increased risk of major bleeding, death in venous thromboembolism (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 28, 2017 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Internal Medicine, Critical Care, Emergency Medicine, Neurology, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news